Cas protein, corresponding gene editing system and usage
Novel Cas proteins and CRISPR-Cas systems with optimized components enhance DNA targeting and editing, addressing the limitations of existing systems and facilitating efficient gene editing and disease treatment.
JP2026516490APending Publication Date: 2026-05-25ヨルテック セラピューティクス カンパニー リミテッド
View PDF 0 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- ヨルテック セラピューティクス カンパニー リミテッド
- Filing Date
- 2024-05-11
- Publication Date
- 2026-05-25
AI Technical Summary
Technical Problem
Existing CRISPR/Cas systems have varying advantages and disadvantages in terms of Cas protein size, guide RNA, and protospacer adjacent motif (PAM) recognition, necessitating the development of novel Cas proteins and CRISPR-Cas systems to meet diverse usage needs.
Method used
Development of novel Cas proteins and CRISPR-Cas systems, including polypeptides with specific amino acid sequences, fusion proteins, optimized polynucleotides, and guide RNAs, which can form complexes to target and edit DNA sequences.
Benefits of technology
The novel systems provide enhanced DNA targeting and editing capabilities, enabling efficient gene editing and disease treatment through precise gene modification.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 2026516490000086 
Figure 2026516490000087 
Figure 2026516490000088
Abstract
This invention provides Cas protein, compositions containing Cas protein, and the CRISPR-Cas system. Furthermore, it provides methods and uses for these compositions and the CRISPR-Cas system. Additionally, it provides cells containing Cas protein, compositions, and the CRISPR-Cas system.
Need to check novelty before this filing date? Find Prior Art